Drug Profile
CAT 5571
Alternative Names: CAT-5571Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Catabasis Pharmaceuticals
- Developer Astria Therapeutics; Bill & Melinda Gates Medical Research Institute
- Class Antifibrotics; Docosahexaenoic acids; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Tuberculosis
- No development reported Cystic fibrosis